Oncology Drug Reference Sheet: Tocilizumab (Actemra®)

Tocilizumab (Actemra^®) was approved in August 2017 for the treatment of chimeric antigen receptor (CAR) T cell–induced cytokine release syndrome. In March 2020, the U.S. Food and Drug Administration approved a randomized, double-blind, placebo-controlled, phase III clinical trial to assess the safety and efficacy of tocilizumab plus standard of care in patients hospitalized with severe COVID-19 pneumonia.